KalVista Pharmaceuticals's total assets for Q2 2026 were $339.93M, an increase of 57.74% from the previous quarter. KALV total liabilities were $322.93M for the fiscal quarter, a 84.83% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.